CytomX Therapeutics (CTMX) Accounts Payables (2014 - 2026)
CytomX Therapeutics (CTMX) posted Accounts Payables of $1.4 million for Q1 2026, up 5.15% on a QoQ basis from $1.3 million in Q4 2025, and up 395.65% year-over-year from $276000.0 in Q1 2025.
CytomX Therapeutics (CTMX) Accounts Payables (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Accounts Payables history runs 13 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- Quarterly Accounts Payables rose 395.65% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 395.65% YoY) and the FY2025 annual result came in at $1.3 million, up 19.58% from the prior year.
- Accounts Payables was $1.4 million for Q1 2026 at CytomX Therapeutics, up from $1.3 million in the prior quarter.
- Across five years, Accounts Payables topped out at $5.2 million in Q3 2022 and bottomed at $227000.0 in Q2 2025.
- A 5-year average of $1.6 million and a median of $1.4 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2025 — Accounts Payables sank 85.95% — and 2026, when it surged 395.65%.
- CytomX Therapeutics' Accounts Payables stood at $2.8 million in 2022, then sank by 48.1% to $1.5 million in 2023, then declined by 25.38% to $1.1 million in 2024, then advanced by 19.58% to $1.3 million in 2025, then grew by 5.15% to $1.4 million in 2026.
- Business Quant data shows CTMX's Accounts Payables at $1.4 million in Q1 2026, $1.3 million in Q4 2025, and $646000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | 1.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.37 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 646,000.00 |
| Jun 30, 2025 | 227,000.00 |
| Mar 31, 2025 | 276,000.00 |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 611,000.00 |
| Mar 31, 2024 | 1.96 Mn |
| Dec 31, 2023 | 1.46 Mn |
| Sep 30, 2023 | 1.71 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 2.20 Mn |
| Dec 31, 2022 | 2.81 Mn |
| Sep 30, 2022 | 5.18 Mn |
| Jun 30, 2022 | 1.92 Mn |
| Mar 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 2.82 Mn |
| Sep 30, 2021 | 1.52 Mn |
| Jun 30, 2021 | 1.76 Mn |